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ABSTRACT  Pemphigus is an autoimmune disease characterized by intraepi-
thelial bullae and erosions in the skin and mucosa. We aimed to evaluate the 
clinical and demographic characteristics of pemphigus vulgaris (PV) patients 
who presented to our Department. Patients who presented to our Depart-
ment between May 2013 and May 2014, were examined dermatologically and 
diagnosed with PV based on clinical, histological and direct immunofluores-
cent findings. Name, family name, and gender of the patients, their complaint 
at presentation, onset time and location of the lesions, the number of lesions, 
systemic treatments received by patients and patients’ medication histories 
were recorded. Forty-nine PV patients were included in our study. Among 
these, 22 (44.9%) were female and 27 (55.1%) male. The mean age of the pa-
tients was 53.28±14.70 (range 23 to 79) years. The mean duration of the dis-
ease was 44.45±45.68 (range 1 to 180) months. The most common complaints 
at presentation were lesion in the mouth (47/49) and lesion/blister in the skin 
(39/49). The onset locations of the lesions were the oropharynx (63.3%), the 
skin and oropharynx combined (16.3%), the skin (18.4%) and the anus (2%). 
The chronological order for the sites of involvement were as follows: first the 
oropharynx then the skin (42.9%), first the skin then the oropharynx (18.4%), 
and the oropharynx and the skin combined (16.3%). Ten patients (20.4%) had 
mucosal involvement and one (2%) had skin involvement alone, whereas 
both mucosal and skin involvements were observed in 38 patients (77.6%). 
Forty-seven patients (95.9%) had not used any medications that could have 
led to pemphigus. One patient had a history of beta-blocker use and another 
had a history of ACE inhibitor prior to the emergence of the pemphigus le-
sions. The clinical and demographic results of the PV patients in our region 
were consistent with those from other studies.
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INTRODUCTION
Pemphigus is an autoimmune disease character-
ized by intraepithelial bullae and erosions in the skin 
and mucous membranes (1). The main characteris-
tic of pemphigus is the occurrence of acantholysis, 
the loss of intercellular connections between the 
epidermal keratinocytes which caused by autoanti-
Acta Dermatovenerol Croat                                 2018;26(2):119-124                                     CLINICAL ARTICLE
ACTA DERMATOVENEROLOGICA CROATICA
120 ACTA DERMATOVENEROLOGICA CROATICA
bodies in the pemphigus serum (2,3). The IgG type 
of autoantibodies against desmoglein 1 and/or 3, a 
cell surface antigen of keratinocytes, are directly de-
tected in immunopathological studies (1-3). Accord-
ing to its clinical and immunopathological character-
istics, the pemphigus family can be categorized into 
four groups: pemphigus vulgaris (PV), pemphigus 
foliaceus (PF), IgA pemphigus, and paraneoplastic 
pemphigus (paraneoplastic autoimmune multior-
gan syndrome, PAMS) (4). The most common clinical 
type of the disease is PV, characterized by loose and 
easily rupturable bullae on normal skin and mucous 
membranes or on an erythematous base (1). Pemphi-
gus is a widespread disease around the world and is 
mostly encountered in patients between 40 and 60 
years of age (5). It is equally prevalent among females 
and males. The incidence of the disease is between 
0.7 and 5 new cases per million per year (6). The main 
goal in the treatment of pemphigus is to achieve the 
remission of the disease in the shortest time and re-
duce the synthesis of autoantibodies. Early system-
atic treatment is necessary to control the disease and 
maintain a long term remission (7,8). 
In our study, we aimed to evaluate the clinical and 
demographic characteristics of the PV patients who 
presented to our Department. 
PATIENTS AND METHODS
Forty-nine patients were enrolled in the study who 
presented to the Department of Dermatology and/or 
Bullous Diseases Clinic at the Faculty of Medicine at 
Karadeniz Technical University between May 2013 
and May 2014. They were examined dermatologically 
and diagnosed with PV based on clinical, histological 
and direct immunofluorescent findings. 
Only the patients whose PV diagnoses were con-
firmed by histopathologic and immunofluorescent 
examinations were included in the study. The biopsy 
material for immunofluorescence was obtained from 
the perilesional skin. Diagnostic criteria included su-
prabasal disintegration and inflammatory infiltration 
in the dermis accompanied by eosinophils in the histo-
pathological examination and intercellular accumula-
tion of IgG in direct immunofluorescence. Name, fam-
ily name, and gender of the patients, their complaint 
at presentation, onset time and location of the lesions, 
the number of lesions, systemic treatments received 
and patients’ medication histories were recorded. 
Enzyme-linked immunosorbent assay (ELISA) was 
used for the detection of anti-Dsg1 and anti-Dsg3 
antibodies (Dermatology Mosaic 7 kit, EUROIMMUN, 
Lübeck, Germany). The ELISA was performed at the 
time of the inclusion in the study.
Statistical analyses were performed using the 
SPSS 13.0 software package (IBM, Armonk, NY, USA). 
Descriptive statistics were summarized as number, 
percentage, mean and standard deviation. 
Results
Of the 49 PV patients included in the study, 22 
(44.9%) were female and 27 (55.1%) male. The female:
male ratio was 1:1.2. The mean age of the patients was 
53.28±14.70 (range 23 to 79) years. The complaints at 
presentation were lesions in the mouth (47/49), dys-
phagia/pain (17/49), nosebleed (9/49), hoarseness 
(12/49), lesion/blister in the skin (39/49) and red eye 
(7/49) (Table 1).
The mean duration of the disease was 44.45±45.68 
(range 1 to 180) months. The onset locations of the le-
sions were the oropharynx (63.3%), the skin and oro-
pharynx combined (16.3%), the skin (18.4%) and the 
anus (2%). The chronological order for the sites of in-
volvement were as follows; first the oropharynx then 
the skin (42.9%), first the skin then the oropharynx 
(18.4%), and the oropharynx and the skin combined 
(16.3%), first the oropharynx then other mucous 
membranes (conjunctiva, anogenital, nasal) (2%), the 
oropharynx plus other mucous membranes combined 
(8.2%), still confined to the oropharyngeal region 
(10.2%) and still confined to the skin (2%) (Table 1).
There were no skin or mucosal lesions at the time 
of admission in 19 out of 49 patients (38.8%). There 
were less than 3 lesions in 7 patients (14.3%), 3-5 le-
sions in 5 patients (10.2%), 6-10 lesions in 6 patients 
(12.2%) and more than 10 lesions in 13 patients 
(26.5%)  
Ten PV patients (20.4%) had mucosal and one 
(2%) had skin involvement alone while both mucosal 
and skin involvements were observed in 38 patients 
(77.6%). Eleven patients (22.4%) had a consanguine-
ous marriage (mother-father) (Table 1).
The standard initial dose of prednisolone was gen-
erally 0.5-1 mg/kg/day in our study. If the disease was 
not controlled after 15 days of treatment on evalua-
tion, the steroid dose was increased by 25-30%. The 
assessment of treatment effectiveness was based on 
the improvement in clinical condition. Epithelializa-
tion of more than 80% of existing erosions and ulcers, 
the cessation of new lesion formation within the last 
15 days and the negativity of Nikolsky’s sign, if Nikol-
sky’s sign is initially positive, were indications that the 
disease was under control. Once the disease was un-
der control, steroids were gradually reduced by 25% 
every two weeks. If the disease could not be con-
trolled, we returned to the initial dose of treatment 
and added adjuvant immunosuppressive therapy if 
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corticosteroids had been initially given alone. Ten of 
the patients (20.4%) did not receive any treatment 
and 39 (79.6%) were under treatment (corticosteroid 
and/or azathioprine).
Twenty patients (40.8%) in our series were treat-
ed with methylprednisolone and azathioprine com-
bined, 16 (32.7%) with methylprednisolone alone and 
three (6.1%) with mycophenolate mofetil. Ten of the 
patients (20.4%) did not receive any treatment and 39 
(79.6%) were under treatment (corticosteroid and/or 
azathioprine).
Diagnosis of PV in 47 patients (95.9%) were made 
by histopathology and this diagnosis was confirmed 
by direct immunofluorescence in 21 (42.9%) of them.
Dsg1 was investigated in 15 (30.6%) of the 49 
patients. The Dsg1 titers varied between <1/10 and 
>1/1000. The Dsg1 titer was <1/10 in seven patients 
(46.7%), >1/10 in two patients (13.3%), >1/100 in two 
patients (13.3%), >1/1000 in one patient (6.7%) and 
>1/32 in three patients (20%).
Dsg3 was investigated in 20 patients (40.8%). The 
Dsg3 titers also varied between <1/10 and >1/1000. 
The Dsg3 titer was <1/10 in five patients (25%), >1/10 
in two patients (10%), >1/100 in three patients (15%), 
>1/1000 in five patients (25%), >1/32 in two patients 
(10%) and >1/320 in three patients (15%).
Forty-seven patients (95.9%) did not use any 
medications that could have led to pemphigus. One 
patient had a history of beta-blocker use and another 
had a history of ACE inhibitor prior to the emergence 
of the pemphigus lesions.
DISCUSSION
Pemphigus is a widespread disease around the 
world. Although the disease is mostly encountered in 
patients between 40 and 60 years of age, it may rarely 
be seen in children and later ages. Studies have shown 
the mean age for the onset of the disease is 46 in South 
Africa, 36.7 in Tunisia, 52 in Macedonia and 57 in Finland 
(5,9-12). In accordance with the literature, the mean age 
of our patients at the time of diagnosis was 50 and the 
age of our patients ranged between 23 and 75 years. 
Although it is usually acknowledged that the dis-
ease is equally prevalent in females and males, some 
Table 1. Clinical and demographic characteristics of PV patients




Complaint at presentation (n, %)
Lesion in the mouth 47 (95.9)
Dysphagia, pain 17 (34.7)
Nosebleed 9 (18.4)
Hoarseness 12 (24.5)
Lesion/blister on the skin 39 (79.6)
Red eye 7 (14.3)
Onset location (n, %)
Oropharynx 31 (63.3)
Skin + Oropharynx 8  (16.3)
Skin 9 (18.4)
Anal region 1 (2)
Chronological order (n, %)
First the oropharynx then the skin 21 (42.9)
First the skin then the oropharynx 9 (18.4)
Oropharynx + skin combined 8 (16.3)
First the oropharynx then other mucous membranes 
(conjunctiva, anogenital, nasal)
1 (2)
Oropharynx + other mucous membranes combined 4 (8.2)
Still confined to the oropharyngeal region 5 (10.2)
Still confined to the skin 1 (2)




Duration of the disease (months) 44.45±45.68
Consanguineous marriage (n, %) 11 (22.4)
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researchers suggest its prevalence is higher in fe-
males while others advocate the opposite (6,13-15). 
In our study, 44.9% of the participants were female 
and 55.1% were male, with a female: male ratio of 
1:1.2. Despite the slightly higher prevalence in males, 
this finding is consistent with those from the litera-
ture, suggesting an equal prevalence of pemphigus 
in both sexes. 
Whereas pemphigus might involve different mu-
cosal tissue, the most commonly involved one is the 
oral mucosa (13,16,17). Some studies reported that 
mucosal involvement in pemphigus was observed 
in up to 100% of the cases (10,12,15). In our study, 
98% of the patients had mucosal involvement. 95.9% 
of our patients had lesions in the mouth, 34.7% had 
dysphagia/pain, 18.4% had nosebleed, 24.5% had 
hoarseness and 14.3% had red eye. In agreement with 
the literature, the prevalence of mucosal involvement 
was high and the most common mucosal involve-
ment was the oral mucosa. 
In PV, the symptoms on the skin usually appear 
after the involvement of the oral mucosa (18). The 
symptoms were observed first in the oral mucosa 
and then on the skin in 42.9% and first on the skin 
and then in the oral mucosa in 18.4% of the patients. 
16.3% of the patients experienced simultaneous in-
volvement of the skin and oral mucosa. In 2% of the 
patients, the involvement of the mouth was followed 
by other mucous membranes (conjunctiva, anogeni-
tal, nasal) while oropharyngeal and other mucous 
had combined involvement in 8.2% of the patients. 
The involvement was in the oral mucosa alone in 
10.2% of the patients and 2% had only dermatologi-
cal symptoms. These findings were consistent with 
those of the literature.
Involvement of the mucosa and/or skin is com-
mon in PV (10,13,15,17). In our study, 98% of the 
patients had mucosal involvement and 79.6% had 
involvement of the skin. These findings support the 
suggestion of common involvement of the skin and/
or mucosa in PV.
In our study, the lesions were located both on the 
skin and in mucosae in 77.6% of the PV patients. Simi-
lar outcomes were exhibited in a Macedonian study 
(76%), whereas a study from Bulgaria reported lower 
prevalence (64.8%) and another from our country 
reported higher prevalence (82.5%) (10,19,20). Our 
study showed that the lesions were located in muco-
sae alone in 20.4% of the PV patients. Similar results 
were obtained again in the Macedonian study (24%); 
however, the study from Bulgaria reported a lower 
(10.8%) and the study from Spain reported a higher 
prevalence (71%) (10,19,21). The study from Bulgar-
ia showed that the lesions were located on the skin 
alone in 24.3% of the patients whereas localization 
on the skin was observed in 6.4% and 6.5% of the pa-
tients in Iran and Turkey (19,20,22). In our study, 2% of 
the patients had lesions located on the skin alone and 
this was a lower rate in comparison to those in the 
literature. This finding confirms that mucosal involve-
ment is more frequent in PV.
The main histopathological finding in PV is in-
traepidermal disintegration. Histopathological as-
sessments of the biopsies in PV patients exhibited 
suprabasal disintegration in 95 to 100% of the pa-
tients (23-26). In our study, 95.9% of the patients had 
suprabasal disintegration and 4.1% had non-specific 
pathological findings; an outcome consistent with 
those from the literature.
In our series of 49 patients clinically and histo-
pathologically diagnosed with PV, 15 (30.6%) were 
examined for anti-Dsg1 antibodies and 20 (40.8%) for 
anti-Dsg3 antibodies. In the literature, the diagnos-
tic sensitivity for anti-Dsg3 antibodies was reported 
to vary between 85 and 100% (25-28). In our study, 
anti-Dsg antibodies were found positive in 75% of the 
patients. The lower rate in our study, in comparison 
to that in the literature, was associated with the ab-
sence of active lesions in our patients who have been 
receiving treatment. Positivity rates for anti-Dsg1 an-
tibody values were reported 46% in Europe, 55.6% in 
Japan, 76.5% in Italy and 77% in Iran (25,27-29). Our 
rate of 53.3% positivity for anti-Dsg1 antibodies was 
close to the rate from the Japanese study.
All participants in our study were investigated for 
consanguineous marriage (mother-father). 22.4% 
of our PV patients had this type of marriage. In the 
studies of Tuncbilek, conducted in different cities in 
Turkey, the rate of consanguineous marriage was be-
tween 20 and 25% and in the study of Baki et al., con-
ducted in the city of Trabzon, the rate was 20% (30, 
31). We believe the findings of our study represent 
the nationwide rate of consanguineous marriage.
CONCLUSION
The clinical and demographic data of the PV 
patients in our region were consistent with other 
studies.
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